RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

NCT06328777 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
12
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Cabaletta Bio